Trial reportThe Lancet. Oncology2017
Dabrafenib plus trametinib in patients with previously untreated BRAF
Trial report in The Lancet. Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06062823 (An Open-label Phase II Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations Categorized According to Structural Based Classification), which is not on this map. Cited by 513 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open-label Phase II Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations Categorized According to Structural Based Classification
Who cites it
513 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Clinical Validation of Tissue and Liquid Companion Diagnostics for BRAF V600E Detection in Non-Small Cell Lung Cancers from the PHAROS Study.Cancer research communications · 2026Trial
- Phase II Study of Dabrafenib and Trametinib in Patients With Tumors WithJCO precision oncology · 2026Trial
- Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.Future oncology (London, England) · 2024Trial
- Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC.Genes & diseases · 2027Review
- Oncogenic mutations in non-small cell lung cancer: from molecular mechanisms to clinical practice.Signal transduction and targeted therapy · 2026Review
- [Personalized drug therapy of metastatic lung cancer].Innere Medizin (Heidelberg, Germany) · 2026Review
- Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives.Lung · 2026Review
- Landscape of Chinese Lung Cancer Patients With Compound Mutations and Acquired Resistance Alterations: A Retrospective Study.International journal of cancer · 2026Article
- Dabrafenib and trametinib-induced hyperglycemia with decreased insulin secretion in a patient with lung adenocarcinoma.JCEM case reports · 2026Article
- Real-World Comparative Effectiveness of First-Line Dabrafenib Plus Trametinib Versus Immunochemotherapy in Patients with Advanced BRAF V600-Mutant Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- New Treatment Strategy and Future Research Direction for BRAF-Mutated Cancer.Cancer science · 2026Review
- Pharmacogenomics in oncology: mutation-targeted therapy and biomarker integration in non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Cost-Effectiveness of First-Line Immunochemotherapy VersusCurrent oncology (Toronto, Ont.) · 2026Article
- Targetable alterations and personalized treatment in ameloblastoma: results from a prospective observational precision oncology study.NPJ precision oncology · 2026Article
- Assessing contribution of effect in oncology combination therapies: lessons learned to inform and optimize future registrational trial designs.The oncologist · 2026Article
- Reduced-Dose Dabrafenib-Trametinib for BRAF V600E-Mutant Lung Adenocarcinoma in a Very Elderly Patient With ECOG PS 2.Respirology case reports · 2026Article
- A Case of Immunotherapy Response to BRAFCancer reports (Hoboken, N.J.) · 2026Article
- Gene testing and prognosis in post-operative recurrent non-small-cell lung cancer: subgroup analyses of WJOG15421L.ESMO open · 2026Observational
453 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byBRAF2017
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBRAF
methodsIn this phase 2, sequentially enrolled, multicohort, multicentre, non-randomised, open-label study, adults (≥18 years of age) with previously untreated metastatic BRAF
findingsBetween April 16, 2014, and Dec 28, 2015, 36 patients were enrolled and treated with first-line dabrafenib plus trametinib. Median follow-up was 15·9 months (IQR 7·8-22·0) at the data cutoff (April 28, 2017). The proportion of patients with investigator-assessed confirmed overall response was 23 (64%, 95% CI 46-79), with two (6%) patients achieving a complete response and 21 (58%) a partial response. All patients had one or more adverse event of any grade, and 25 (69%) had one or more grade 3 or 4 event. The most common (occurring in more than two patients) grade 3 or 4 adverse events were pyrexia (four [11%]), alanine aminotransferase increase (four [11%]), hypertension (four [11%]), and vomiting (three [8%]). Serious adverse events occurring in more than two patients included alanine aminotransferase increase (five [14%]), pyrexia (four [11%]), aspartate aminotransferase increase (three [8%]), and ejection fraction decrease (three [8%]). One fatal serious adverse event deemed unrelated to study treatment was reported (cardiorespiratory arrest).
interpretationDabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAF
fundingNovartis.
Indexed as
Identifiers
28919011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.